Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

Coiffier, B.; Haïoun, Corinne; Ketterer, Nicolas; Engert, Andreas; Tilly, H; Ma, Dengyan; Johnson, Peter; Lister, A.; Feuring Buske, Michaela; Radford, John; Capdeville, Renaud; Diehl, Volker; Reyes, F

doi:10.1182/blood.v92.6.1927

Public

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

Published in PubMed • Sep 15, 1998

Authors:

B. Coiffier

Corinne Haïoun

Nicolas Ketterer

Abstract

Rituximab, a chimeric monoclonal antibody that binds specifically to the CD20 antigen, induced objective responses in 50% of patients with low-grade or follicular B-cell lymphoma. Because most nonfollicular B-cell lymphomas also express the CD20 antigen, we conducted a phase II study to evaluate the...

Subject

Rituximab

Medicine

Tolerability

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!